Pegvisomant-Induced Cholestatic Hepatitis in an Acromegalic Patient with UGT1A128 Mutation

Table 1

Chronological development and values of alkaline phosphatase (APh), γ-glutamyltranspeptidase (GGT), total bilirubin (T. Bil), ferritin, transferrin saturation (TSAT), and iron during the combination therapy with PEGv and after stopping this treatment.

	During combination therapy		After stopping combination therapy
	2 Months	5 Months	10 Days	1 Month	2 Months	3 Months	4 Months
APh (40–120 UI/L)	136	272	242	99	99	92	80
GGT (8–61 UI/L)			549	166	166	77	17
T. Bil (0.1–1 mg/dL)	0.4	2.5	1.9	0.64	0.64	0.61	0.61
Ferritin (30–400 ng/mL)			4836	763	595	374	191
Transferrin (200–360 ug/dL)			212	198	194	210	244
TSAT (15–50%)			104	72			50
Iron (59–158 ug/dL)			180	180			154